Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00150254 · ClinicalTrials.gov registry record · Phase 2
12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation.
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 625
- Enrollment target
NCT00150254 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 625 participants.
The verdict
NCT00150254, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 625 participants
- Enrollment target
Study Summary
The purpose of the study is to measure the safety and efficacy of four dosing strategies of CP-526,555 for 12 weeks compared with placebo for smoking cessation. Post-treatment follow-up of smoking status to one year from randomization was performed in a non-treatment extension Protocol A3051018
Interventions
- DRUG CP-526,555 (varenicline)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 625 participants |
| Start Date | 2001-09 |
| Est. Completion | 2002-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00150254
The ClinicalTrials.gov registry entry for NCT00150254 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 625 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CP-526,555 (varenicline) is the first listed.
NCT00150254 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00150254 about?
NCT00150254 is a clinical study titled "12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation.". The purpose of the study is to measure the safety and efficacy of four dosing strategies of CP-526,555 for 12 weeks compared with placebo for smoking cessation. Post-treatment follow-up of smoking status to one year from randomization was performed in a non-treatment extension Protocol A3051018
What is the current status of trial NCT00150254?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 625 participants. The study started on 2001-09. Estimated completion is 2002-10.
What interventions are being tested in trial NCT00150254?
The interventions under investigation include: CP-526,555 (varenicline) (DRUG).
Who is sponsoring clinical trial NCT00150254?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.